Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 2/20 | 0.87 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.87 |
| ▸ | HRH3 | Q9Y5N1 | 15/20 | 0.79 |
| ▸ | PSMB1 | P20618 | 1/20 | 0.70 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.70 |
| ▸ | PSMB2 | P49721 | 1/20 | 0.70 |
| ▸ | MEN1 | O00255 | 1/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14970686 | 1.00 | LTA4H (0.87) | LTA4HPTGS2HRH3PSMB1PSMB5 | |
| Hydrochloric Acid SCHEMBL14966884 | 0.98 | LTA4H (0.84) | LTA4HPTGS2HRH3PSMB1PSMB5 | |
| SCHEMBL7819691 | 0.98 | LTA4H (0.90) | LTA4HPTGS2HRH3PSMB1PSMB5 | |
| SCHEMBL7134872 | 0.90 | LTA4H (1.00) | LTA4HPTGS2HRH3PSMB1PSMB5 | |
| SCHEMBL21004113 | 0.89 | HRH3 (0.84) | LTA4HPTGS2HRH3MEN1KMT2A | |
| SCHEMBL11093348 | 0.88 | HRH3 (1.00) | LTA4HPTGS2HRH3MEN1KMT2A | |
| SCHEMBL491769 | 0.86 | HRH3 (0.97) | LTA4HPTGS2HRH3MEN1KMT2A | |
| SCHEMBL12204133 | 0.86 | PSMB1 (0.83) | LTA4HPTGS2HRH3PSMB1PSMB5 | |
| SCHEMBL3578646 | 0.85 | HRH3 (0.90) | LTA4HHRH3PSMB1PSMB5PSMB2 | |
| SCHEMBL12440469 | 0.85 | MCHR1 (0.78) | LTA4HPTGS2HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070191429-A1 | PPAR ACTIVATORS | PFIZER INC. (US) | 2007-08-16 | — | — | US | disclosed |
| US-20040019052-A1 | Pyrazolopyridines and pyrazolopyridazines as antidabetics | SMITHKLINE BEECHAM P.L.C. (GB) | 2004-01-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070191429-A1 | PPAR ACTIVATORS | PPARA, PPARG, PPARD | LTA4H 803/4885PTGS2 831/4885HRH3 2959/4885 |
| US-20040019052-A1 | Pyrazolopyridines and pyrazolopyridazines as antidabetics | PDXK, GCK, IAPP | LTA4H 2800/4885PTGS2 3578/4885HRH3 3252/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.